Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 6, 2011, Pages 388-396

  McCracken, N ^a   Lahu, G ^a   Bethke, T D ^a  

^a Nycomed GmbH   (Germany)

Author keywords

Coagulation; Pharmacodynamics; Pharmacokinetics; Roflumilast; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; PLACEBO; ROFLUMILAST; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; EOSINOPHILIA; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AMINOPYRIDINES; ANTICOAGULANTS; BENZAMIDES; CYCLOPROPANES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; STEREOISOMERISM; WARFARIN;

EID: 79959437159     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201523     Document Type: Article

References (34)

1. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-694.
2. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF for the M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374: 695-703.
3. Hatzelmann A, Morcillo EC, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010; 23: 235-256.
4. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Morike K, David M, Knoerzer D, Wurst W, Gleiter CH. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007; 47: 26-36.
5. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124: 970-979.
6. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 2006; 62: 291-296.
7. Kim KY, Epplen K, Foruhari F, Alexandropoulos H. Update on the interaction of rifampin and warfarin. Prog Cardiovasc Nurs. 2007; 22: 97-100.
8. Lu Y, Won KA, Nelson BJ, Qi D, Rausch DJ, Asinger RW. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm. 2008; 65: 947-952. (Pubitemid 351680043)
9. Dandekar SS, Laidlaw DA. Suprachoroidal haemorrhage after addition of clarithromycin to warfarin. J R Soc Med. 2001; 94: 583-584. (Pubitemid 33078997)
10. Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med. 2005; 20: 653-656. (Pubitemid 41026254)
11. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, Hennessy S. Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther. 2008; 84: 581-588.
12. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother. 2008; 6: 33-36. (Pubitemid 351722953)
13. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095-1106. (Pubitemid 40720733)
14. Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm. 2006; 12: 640-648. (Pubitemid 47407592)
15. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. The American Heart Association; American College of Cardiology Foundation. Circulation. 2003; 107: 1692-1711.
16. Wingard LB, O'Reilly RA, Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clin Pharmacol Ther. 1978; 23: 212-217.
17. Banfield CR, O'Reilly RA, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man. Further stereochemical and metabolic considerations. Br J Clin Pharmacol. 1983; 16: 669-675.
18. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, Goulart DA. The warfarin-sulfin-pyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986; 39: 15-24.
19. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003; 3: 221-230. (Pubitemid 37280710)
20. Redman AR. Implications of cytochrome P450 aC9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy. 2001; 21: 235-242. (Pubitemid 32119201)
21. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106: 2329-2333.
22. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance doses of warfarin in Japanese, Caucasians and African Americans. Pharmacogenet Genomics. 2006; 16: 101-110.
23. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65: 365-375.
24. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet. 2006; 43: 740-744. (Pubitemid 44483917)
25. Duursema L, Muller FO, Hundt HKL, Heyns A du P, Meyer BH, Luus HG. Model to detect warfarin-drug interactions in man. Drug Investigation 1992; 4: 395-402.
26. Stirling Y, Howorth DD, Stockley R, Blond R, Towler LM, Harding SM. Comparison of bioavailability and anticoagulant activities of two warfarin formulations. Br J Haematol. 1982; 51: 37-46. (Pubitemid 12101976)
27. U.S. Department of Health and Human Services, Food and Drug Administration - Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville; 2003.
28. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther. 1996; 34: 25-30.
29. Mohammed Abdul M, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008; 154: 1691-1700.
30. Faaij RA, Griensven JMT, Schoemaker HC, van Amsterdam RGM, Cohen AF. The effect of warfarin on the pharmacokinetics and pharmacodynamcis of napsagatran in healthy male volunteers. Eur J Clin Pharmacol. 2001; 57: 25-29. (Pubitemid 32391408)
31. Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990; 30: 743-750. (Pubitemid 20377605)
32. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr. London; 2010.
33. MacKichan JJ. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokin. 1984; 9: 32-41. (Pubitemid 14179499)
34. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol. 1994; 37: 125-128. (Pubitemid 24213753)